In addition, the interplay between microbiota and other immuno-oncology modalities other than PD1/PD-L1 inhibitors such as cancer vaccine, T cell-targeted therapy, and oncolytic virus therapy needs more investigation, which may help to illustrate whether the presence of beneficial consortium is applicable and overlapping in a broad spectrum of immunotherapy. This evidence concerns the gene PDCD1 and cancer.